[1]Zhang L, Wang F, Wang L, et al.Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012 Mar 03; 379(9818)
[2]Kolesnyk I, Dekker FW, Boeschoten EW, et al.Time dependent reasons for PD technique failure and mortality. Perit Dial Int 2010; 30: 170-177.
[3]Coester AM, Smit W, Struijk DG, et al.Longitudinal analysis of fluid transport and their determinants in PD patients. Perit Dial Int 2014; 34: 195-203.
[4]Devuyst O, Margetts PJ, Topley N.The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010; 21:1077-85.
[5]Witowski J, J?rres A.Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical Consequences. Perit Dial Int 2005; 25(Suppl 3): S31-S34.
[6]Pecoits-Filho R, Stenvinkel P, Heimburger O, et al.Beyond the membrane-the role of new PD solutions in enhancing global biocompatibility. Kidney Int Suppl 2003; 2003(88): S124-S132.
[7]Nau B, Schmitt CP, Almeida M, et al.BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children. BMC Nephrol 2004; 2004(5): 14.
[8]Cho Y, Johnson DW, Badve SV, Craig JC, Strippoli GF, Wiggins KJ.The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int 2013; 84:969-79.
[9]Johnson DW, Cho Y, Livingston BE, et al.Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77:904-12.
[10]Kawanishi K, Honda K, Tsukada M, Oda H, Nitta K.Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int 2013; 33:242-51.
[11]Hamada C, Honda K, Kawanishi K, et al.Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs 2015; 18:243–50.
[12]Tawada M, Ito Y, Hamada C, et al.Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients. PLoS ONE 2016; 11(4):e0154644.
[13]Bargman JM, Thorpe KE, Churchill DN.Relative Contribution of Residual Renal Function and Peritoneal Clearance to Adequacy of Dialysis: A Reanalysis of the CANUSA Study. J Am Soc Nephrol 2001; 12: 2158–2162.
[14]Johnson DW, Brown FG, Clarke M, et al.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23(6): 1097-1107.
[15]Htay H, Cho Y, Pascoe EM, et al.Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The ANZ Trial. Perit Dial Int 2017; 37(3)
[16] Htay H, Johnson DW, Wiggins KJ, et al.Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2018; 10, 26; 10。
[17]Tranaeus A.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. Perit Dial Int 2000; 20: 516-523.
[18] Williams JD, Topley N, Craig KJ, et al; The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int 2004; 66: 408–-418.
[19]Tawada M, Hamada C, Suzuki Y, et al.Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients. Clin Exp Nephrol 2019; 23(5)
[20]Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T.Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Perit Dial Int 2012; 32(2):159–67.
[21]Nataatmadja MS, Johnson DW, Pascoe EM, et al.balAssociations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the ANZ Trial. Perit Dial Int 2018; 38(5)
[22] Choi HY, Kim DK, Lee TH, et al.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int 2008; 28(2): 174-182.
[23]Szeto CC, Chow KM, Lam CW, et al.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucosedegradation products--a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22(2): 552-559.
[24]Cho Y, Johnson DW, Craig JC, et al.Biocompatible dialysis fluids for peritoneal dialysis[J].Cochrane Database of Systematic Reviews, 2014, 27(3):C-D007554
[25]Van Diepen ATN, Coester AM, Janmaat CJ, et al.Comparison of longitudinal membrane function in peritoneal dialysis patients according to dialysis fluid biocompatibility. Kidney Int Rep 2020; 5: 2183–2194.
[26]Elphick EH, Teece L, Chess JA, et al.Biocompatible solutions and long-term changes in peritoneal solute transport. Clin J Am Soc Nephrol 2018; 13: 1526–1533.
[27]Kawanishi H, Kawaguchi Y, Fukui H, et al.Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729–37.
[28]Balasubramaniam G, Brown EA, Davenport A, et al.The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009; 24:3209–15.
[29]Korte MR, Sampimon DE, Lingsma HF, et al.Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int. 2011; 31:269–78.
[30]Hendriks PEM, Ho-dac-Pannekeet MM, van Gulik TM, et al.Peritoneal sclerosis in peritoneal dialysis patients: analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136–143.
[31]Sampimon DE, Vlijm A, Struijk DG, et al.Encapsulating peritoneal sclerosis in patients on peritoneal dialysis. Neth J Med 2008; 66: 396.
[32]Betjes MGH, Habib SM, Boeschoten EW, et al.Significant decreasing incidence of encapsulating peritoneal sclerosis in the Dutch population of peritoneal dialysis patients. Perit Dial Int 2017; 37: 230–234.
[33]Nakayama M, Miyazaki M, Honda K, et al.Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int 2014; 34(7)
[34]Kitterer D, Braun N, Alscher MD, et al.The number of patients with severe encapsulating sclerosis is decreasing in a large referral center in Germany. Int J Nephrol Renovasc Dis 2016; 5: 183–186.
[35]Ho Yung Lee, Hoon Young Choi, Hyeong Cheon Park, et al.Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21(10):2893- 9
[36]Williams JD, Craig KJ, Topley N, et al.Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470–9.
[37]Honda K, Hamada C, Nakayama M, et al.Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008; 3:720–8.
[38]Garcia-Lopez E, Lindholm B, Davies S.An update on peritoneal dialysis solutions. Nat Rev Nephrol 2012; 8(4):224–33.
[39]Sherif AM, Nakayama M, Maruyama Y, et al.Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant 2006; 21:1675–81.
[40]Nakamoto H, Hamada C, Shimaoka T, et al.Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients. J Artif Organs 2014; 17:60–8.
[41]Perl J, Nessim SJ, Bargman JM.The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? Kidney Int 2011; 79(8):814–24.
[42]Yohanna S, Alkatheeri AM, Brimble SK, et al.Effect of neutral-pH, lowglucose degradation product peritoneal dialysis solutions onresidual renal function, urine volume, and ultrafiltration: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2015; 10(8):1380–8.
[43]del Peso G, Jimenez-Heffernan JA, Selgas R, et al.Biocompatible dialysis solutions preserve peritoneal mesothelial cell and vessel wall integrity. a case–control study on human biopsies. Perit Dial Int 2016; 36:129–34.
[44]Fusshoeller A, Plail M, Grabensee B, Plum J.Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19(8)
[45]Edwina A Brown, Peter G Blake, Neil Boudville, et al.International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int 2020 07; 40(4)
